In vitro diagnostics (IVDs) are an essential component of the healthcare sector, and their product quality directly impacts the accuracy of clinical diagnoses. In international trade, accurately identifying the performance, compliance, and applicability of IVD products is crucial. This article will explore how to effectively identify IVD products from the perspectives of technical standards, certification marks, and testing methods.
First, verification of technical parameters is central to the identification of IVD products. Different diagnostic reagents or instruments have clear sensitivity, specificity, and precision specifications for specific test items (such as blood glucose and infectious disease markers). Foreign trade practitioners should carefully review the technical data in the product instructions and compare them with the industry standards of the target market (such as the EU CE mark, US FDA requirements, or China NMPA standards) to ensure that the product complies with the regulatory requirements of the importing country.
Second, reviewing certification marks is crucial for determining product legality. Authentic IVD products typically bear certification marks issued by authoritative organizations, such as the EU CE IVDR mark, US CLIA exemptions, or China Medical Device Registration Certificates. These marks not only verify that the product has undergone rigorous testing but also indicate that the production process adheres to quality management standards (such as ISO 13485). Foreign trade companies should require suppliers to provide originals or official copies of certification documents to avoid customs clearance delays or market access failures due to incomplete documentation.
In addition, validation of testing methods is also a crucial step. Some in vitro diagnostic products rely on specific instruments or reagent combinations, requiring laboratory comparative testing to verify their actual performance. For example, the cross-reactivity rate of immunodiagnostic reagents or the amplification efficiency of molecular diagnostic products can be verified by third-party testing agencies. In international trade, buyers are advised to conduct sampling and testing before signing a contract to ensure that the product conforms to the advertised performance.
In summary, the identification of in vitro diagnostic products requires a comprehensive assessment based on technical parameters, certification documents, and actual test results. Foreign trade practitioners should establish a systematic evaluation process to reduce procurement risks and contribute to the healthy development of the global medical diagnostics industry.